Guardant Health, Inc.

GH Healthcare Diagnostics & Research

Guardant Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $982.0 million, up 32.9% from fiscal 2024.

Revenue
+36.1%
EPS
−25.7%
Free cash flow
+18.7%
Total debt
+34.8%

Quarter to September 2026, against a year earlier

149.85 3.58 −2.33%
Market cap
$20.6B
P/E
0.0×
Fwd P/E
−55.6×
Dividend yield
—
F-score
5/9
Altman Z
2.02
Beneish M
−2.78
Dividend safety
n/a

Guardant Health, Inc. 10-Q filed Jul 30, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed · accepted 4:46 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Jul 30, 2025: 11 added · 21 removed · 36 modified; 8 with only figures updated; 1 moved without change